Novo Nordisk's GLP-1 Growth Engine: Why Strong Demand Is Not Producing Strong Revenue Growth
Novo Nordisk is a Danish pharmaceutical company that has worked on diabetes treatment for more than a century. The reason it came to be valued as a very different kind of company during the 2020s is that one class of medicine, the GLP-1 receptor agonists, expanded from diabetes into obesity and then into cardiovascular risk reduction. Yet the second-quarter 2026 results show a gap: the products are selling well, while growth for the company as a whole is low. This article examines where that gap comes from. Rather than listing figures, it follows the structure through which revenue growth is actually produced. Table of Contents Why the GLP-1 Business Was Built This Way The Structure and Requirements of the Wegovy Range What the Second-Quarter 2026 Data Shows The Core Mechanism Behind Revenue Growth How Eli Lilly's Structure Differs Limitations of the Current Business Structure Frequently Asked Questions Summary 1. Why the GLP-1 Business Was Built This Way Semagl...